Aortic Stents Grafts Market Size, Share, Industry, Forecast and outlook (2024-2031)

Aortic Stents Grafts Market is segmented By Product Type (Abdominal Aortic Stent Graft , Thoracic Aortic Stent Graft), By Material (Nitinol, Cobalt-Chromium, Steel, Polytetrafluoroethylene (PTFE), Polyester/Dacron, Others), By Application (Abdominal Aortic Aneurysms (AAAs), Thoracic Aortic Aneurysms (TAAs) ), By End-User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others), and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031.

Aortic Stent Grafts Market Overview

Global Aortic Stent Grafts Market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY % during the forecast period 2024-2031.

An aortic stent graft is a medical device used to reinforce and support the weakened wall of the aorta, the largest artery in the body. It is a minimally invasive procedure that involves placing a fabric-covered, metal mesh tube (stent) within the affected section of the aorta, preventing it from rupturing or further expanding.

Stent-graft diversity has broadened the available characteristics that may be selected for the treatment of an individual patient. Various options exist for stent-graft fixation, sealing, patency, sizing and durable exclusion of aortic aneurysms. Radiopacity, deployment precision, ease of use and access issues in terms of sheath size and flexibility are additional important attributes. An essential feature of all stent grafts is a method of fixation to inhibit migration after deployment. Aortic blood flow delivers a constant force that pushes the proximal end of a stent-graft caudad. In tortuous anatomy, vector forces tend to cause the separation of components and craniad migration of the distal components. Aortic lengthening forces intercomponent separation.

Aortic Stent Grafts Market Scope

For more details on this report - Request for Sample

Market Dynamics: Drivers

Rising advancements in aortic stent grafts 

The rising advancements in aortic stent grafts are expected to drive the market over the forecast period. The major market players are constantly refining the design of aortic stent grafts to improve performance and durability. This includes innovations in graft materials, such as introducing new biocompatible coatings or using novel biomaterials that promote better integration with the patient's anatomy.

For instance, on May 11, 2021, Endologix launched the first implant of its Alto abdominal stent graft in Canada following approval from Health Canada. The Alto abdominal stent graft system is the latest generation in polymer-based therapies for abdominal aortic aneurysm (AAA) patients. The device utilizes a low-profile delivery system and unlike standard endovascular aneurysm repair (EVAR) devices, it features an exclusive conformable sealing ring that moulds in situ to the patient’s specific aortic neck anatomy.

Coatings that release drugs or biologically active agents can help inhibit inflammation, promote endothelialization and prevent complications such as stent graft migration or restenosis. These technologies aim to improve the long-term durability and performance of the implanted graft. These specialized grafts feature openings or branches that align with the patient's renal arteries, visceral arteries or other important branching vessels. They allow for endovascular repair of complex aortic aneurysms involving these vital arteries, expanding the eligibility for minimally invasive treatment.

For instance, on September 08, 2023, the Castor Branched Aortic Stent-Graft and Delivery System (Castor Branched Stent-Graft), the Minos Abdominal Aortic Stent-Graft and Delivery System (Minos Stent-Graft) and the Hercules Thoracic Stent Graft System with Low Profile Delivery System (Hercules LP Stent Graft), developed by Endovastec have been granted registration approval from the Thailand Food and Drug Administration (TFDA). These three products are the key offerings from Endovastec in endovascular intervention for thoracic and abdominal aortic diseases. The Castor Branched stent graft, used for endovascular treatment of aortic arch dissection and is the first approved branched aortic stent graft for the market worldwide. Since its launch, it has been approved in 14 countries, with over 18,000 implants.

In addition, on June 19, 2023, Endospan announced its initial experience with its custom-made NEXUS DUO Aortic Arch Stent Graft System. The NEXUS DUO is custom-built based on each patient's anatomy and physician's preferences. The NEXUS DUO is built on the clinically established technology of the NEXUS Aortic Arch Stent Graft System. NEXUS is designed to mitigate stroke risks and provide high procedural success.

Further, the increasing prevalence of abdominal and thoracic aortic aneurysms, rising regulatory approvals and product launches, increasing awareness, increasing preference for minimally invasive procedures and increasing advancements in the aortic stent grafts are the factors expected to drive the market over the forecast period.

Restraints

Factors such as the high cost associated with aortic stent grafts, complications associated with these devices, limited awareness, regulatory challenges and some device-related challenges are the factors expected to hamper the market. 

Aortic Stent Grafts Market Segment Analysis

The global aortic stent grafts market is segmented based on product type, material, application, end-user and region.

The abdominal aortic stent graft segment accounted for approximately 56.5% of the aortic stent grafts market share

The abdominal aortic stent graft segment is expected to hold the largest market share over the forecast period. Abdominal aortic stent grafts are typically deployed through minimally invasive endovascular procedures, where the graft is inserted through small incisions in the groin area and guided to the site of the aneurysm using imaging techniques such as fluoroscopy. Once in position, the stent graft is expanded, sealing off the weakened section of the aorta and preventing the risk of rupture. These advanced features and increasing abdominal aortic aneurysms is increasing the demand for abdominal aortic stent grafts.

For instance, on May 05, 2020, Terumo Aortic cleared the US Food and Drug Administration (FDA) approval of the TREO Abdominal Aortic Stent-Graft System for sale in the United States for the treatment of patients with abdominal aortic aneurysms (AAA). TREO is the only device commercially available for endovascular aneurysm repair (EVAR) with dual proximal fixation and lock stent technology offering physicians the next advancement in endovascular device solutions. It is a three-piece design featuring in situ limb adjustability and provides a wide range of aortic device configurations to specifically address the anatomy of each patient. TREO is designed for accurate, controlled and safe deployment.

Endovascular repair using abdominal aortic stent grafts involves smaller incisions, reduced blood loss, shorter hospital stays and faster recovery times compared to open surgical repair. The less invasive nature of endovascular repair using stent grafts expands the pool of patients eligible for treatment, including those who may be deemed unfit for open surgery due to advanced age, comorbidities, or anatomical considerations. 

For instance, on January 04, 2023, Endovastec received registration approval from the Ministry of Food and Drug Safety of Korea (MFDS) for its independently developed Minos Abdominal Aortic Stent-Graft and Delivery System (Minos Stent Graft System). This is the first time the Minos Stent Graft System has received marketing approval in an overseas market in Asia. The Minos Stent-Graft System is designed for the endovascular treatment of infrarenal abdominal aortic aneurysms. It represents Endovastec’s next-generation abdominal aortic stent graft system and is the first domestically produced product with a delivery sheath outer diameter reduced to 14F, significantly lowering the requirements for vascular access during surgery.

Geographical Analysis

North America accounted for approximately 41.3% of the market share 

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing demand for aortic stent grafts in the region. North America especially the United States is a well-known hub for its strong presence of major players such as medical device companies. This presence of major players in the region continually develops and introduces new technologies and products in the field of aortic stent grafts, which leads to market dominance in the region.

For instance, on May 05, 2023, Terumo Aortic cleared the US Food and Drug Administration (FDA) approval of the RelayPro thoracic stent graft device for the treatment of dissection and transection in the USA. RelayPro delivers uncompromised clinical performance in the lowest commercially available profile and is indicated for all pathologies of the descending thoracic artery; aneurysms, penetrating atherosclerotic ulcers, transection and dissection. RelayPro offers unparalleled accuracy, proven efficacy and durability as well as the widest range of sizes, tapering and configurations on the market, designed to expand the treatment of thoracic endovascular aortic repair (TEVAR) to patients with smaller access vessels.

In addition, there is an increasing demand for aortic stent grafts due to the increasing prevalence of aortic aneurysms in the region, which is expected to drive the market. For instance, according to Penn Medicine Lancaster General Health, 2022, each year, about 200,000 people in the U.S. are diagnosed with an abdominal aortic aneurysm (AAA), a bulge in the lower part of the aorta. And according to the National Institute of Health, 2023, in the United States, about 13000 patients die because of aortic disease each year, and thoracic aortic aneurysm is the 18 most common cause of death among all individuals. TAA has an incidence of 10 cases per 100000 patient.

Competitive Landscape

The major global players in the aortic stent grafts market include Medtronic plc, Cardinal Health, Terumo Corporation, Artivion, Inc, MicroPort Scientific Corporation, Cordis, Endoron Medical Ltd., Lombard Medical, Endologix LLC and Cook Medical Inc. among others. 

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global aortic stent grafts market. The coronavirus disease 2019 (COVID-19) outbreak is responsible for 114,315,846 confirmed cases, including 2,539,427 deaths worldwide, as reported by the World Health Organization, its catastrophic consequences on health have impacted all aspects of medical practice including aortic stent graft procedures from the availability of, and accessibility to, health services, to patients. This led to a decline in procedure volumes and subsequently impacted the demand for aortic stent grafts.

Why Purchase the Report?

• To visualize the global aortic stent grafts market segmentation based on product type, material, application, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of aortic stent grafts market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global aortic stent grafts market report would provide approximately 69 tables, 69 figures and 187 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies